

OFFICE OF THE SECRETARY OF STATE

SHEMIA FAGAN
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION

STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

TEMPORARY ADMINISTRATIVE ORDER
INCLUDING STATEMENT OF NEED & JUSTIFICATION

BP 44-2022

CHAPTER 855

BOARD OF PHARMACY

FILED

10/17/2022 2:25 PM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Protocol Compendium revised to include COVID-19 Antiviral protocol

EFFECTIVE DATE: 10/17/2022 THROUGH 04/14/2023

AGENCY APPROVED DATE: 10/13/2022

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St

Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

NEED FOR THE RULE(S):

Temporarily adopts COVID-19 Antiviral protocol as requested by the Oregon Health Authority and the Public Health and Pharmacy Formulary Advisory Committee to increase patient access to COVID-19 antiviral medication as soon as possible.

JUSTIFICATION OF TEMPORARY FILING:

Per the Oregon Health Authority and the Public Health and Pharmacy Formulary Advisory Committee, pharmacists need the ability to prescribe PAXLOVID via a statewide drug therapy management protocol to provide critical treatment of COVID-19 infection. Oregon pharmacists are more familiar using statewide protocols for prescribing services than an FDA Emergency Use Authorization. Access to affordable COVID-19 antiviral medication in a timely manner protects public health and safety.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

Conditions: Statewide Drug Therapy Management Protocol for COVID-19 Antiviral

https://www.oregon.gov/pharmacy/Documents/COVID-19_Antigen_Self_Test_Protocol.pdf

ORS 689.689 https://www.oregonlegislature.gov/bills_laws/ors/ors689.html

AMEND: 855-020-0300

RULE SUMMARY: Temporarily adopts a COVID-19 Antiviral Protocol and amends the current protocol compendia by adding "COVID-19 Antiviral Protocol". Increases equitable access and reduces barriers for patients seeking treatment for COVID-19.

CHANGES TO RULE:

855-020-0300

Protocol Compendium

A Pharmacist may prescribe, via statewide drug therapy management protocol and according to rules outlined in this Division, an FDA-approved drug and device listed in the following compendium:¶¶

- (1) Continuation of therapy (v. 06/2021);¶
 - (2) Conditions¶
 - (a) Cough and cold symptom management¶
 - (A) Pseudoephedrine (v. 06/2021);¶
 - (B) Benzonatate (v. 06/2021);¶
 - (C) Short-acting beta agonists (v. 06/2021);¶
 - (D) Intranasal corticosteroids (v. 06/2021);¶
 - (b) Vulvovaginal candidiasis (VVC) Protocol (v. 06/2021);¶
 - (c) COVID-19 Monoclonal Antibody (mAb) Protocol (v. 12/2021); and¶
 - (d) COVID-19 Antigen Self-Test Protocol (v. 12/2021); and¶
 - (e) COVID-19 Antiviral Protocol (v. 10/2022).¶
 - (3) Preventative care¶
 - (a) Emergency Contraception (v. 06/2021);¶
 - (b) Male and female condoms (v. 06/2021);¶
 - (c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT Protocol (v. 06/2022);¶
 - (d) Travel Medications Protocol (v. 06/2021);¶
 - (e) HIV Post-exposure Prophylaxis (PEP) Protocol (v. 12/2021); and¶
 - (f) HIV Pre-exposure Prophylaxis (PrEP) Protocol (v. 6/2022).¶
- [Publications referenced are available for inspection in the office of the Board of Pharmacy per OAR 855-010-0021.]
- Statutory/Other Authority: ORS 689.205
- Statutes/Other Implemented: ORS 689.645, ORS 689.649